Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Doug Markle who wrote (5453)	10/5/1998 12:51:00 PM
From: Izzy	Respond to of 6136

SEQU has been acquired by AZA. So there is buying going on in the biotech industry.

To: Doug Markle who wrote (5453)	10/5/1998 2:00:00 PM
From: billkirn	Respond to of 6136

Doug: Business is business. The rights are to protect the company from an unfriendly takeover. These rights can be changed immediately by the board or a good deal. Bill

To: Doug Markle who wrote (5453)	10/5/1998 2:35:00 PM
From: John Metcalf	Read Replies (1) \| Respond to of 6136

Doug, my understanding is that the rights transfer with the shares, and will continue to do so, except to a buyer of 15% or more of the company shares. If a fellow SI-er doesn't come along soon and give a more definitive opinion, surely Ms. Nichols would clarify this issue. Since the value of the rights is determined by Board action subsequent to the "trigger" event, that value would be set to zero to facilitate a friendly merger, if one is ever proferred and accepted. I have no knowledge that there is such an offer, nor ever will be.